Annovis Bio, Inc.

Recent News

  • Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

    Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and Alzheimer's disease this quarter. We received positive feedback from the U.S. Food and Drug Administration (FDA)...

    2022-05-04 8:30 AM EDT
  • Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

    Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a part of the National Institutes of Health. Under this CRADA, NIA and Annovis will collaborate to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles (EV) containing potential biomarkers of neuronal function and viability. The team...

    2022-04-28 4:30 PM EDT
  • Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

    Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pleased to participate in World Parkinson's Day to promote greater awareness of how Parkinson's disease affects those living with the progressive disease and support research efforts to develop disease-modifying treatment options.An estimated one million people in the U.S. and more than ten million people worldwide live with Parkinson's, making it the second-most common neurodegenerative...

    2022-04-11 8:30 AM EDT
  • Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

    Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th. Management will present an update on business activities. The pre-recorded presentation can be viewed during the days of the event. Sign up here to access the...

    2022-03-23 8:30 AM EDT
  • Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)

    Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, will present an update on the trial designs of the Company's upcoming Phase 3 trials evaluating Buntanetap in Parkinson's disease (PD) during the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™ 2022), hosted in-person in Barcelona, Spain, and virtually from March 15-20, 2022.Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of...

    2022-03-18 8:30 AM EDT
  • Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

    Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will be presenting at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™ 2022). The hybrid conference will be hosted in-person in Barcelona, Spain, and virtually from March 15-20, 2022. Maria L. Maccecchini, Ph.D., Founder, President, and CEO, and Cheng Fang, Ph.D., Senior Vice President of Research & Development, will...

    2022-03-08 8:30 AM EST
  • Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference

    Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.Management will present an update on business activities on Tuesday, March 8, 2022, at 12:50 p.m. ET. A live webcast of the presentation may be accessed at: https://wsw.com/webcast/cowen108/anvs/2030328. An archived replay of the webcast will be available on the Company's...

    2022-03-03 8:30 AM EST
  • Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease

    Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) with regard to the Company's planned Phase 3 clinical studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company's submission of...

    2022-01-25 9:00 AM EST